Meta-analysis of 2 assessment. analysis. cities - Brisbane, Sydney. High heterogeneity. for 65+ years lCD9: 390-429; ICDI0: I00-I52, I97.0, I97.1, I98.1 Ischaemic heart Not assessed in 4 1.2% (0.5-1.9%) per n/a n/a n/a No CRF disease cities study 10 ug/m3 recommended. () () Random effects No effect in 15-64 years: No estimate. Australian 2-cities effect 24-hour average. meta-analysis (). 65+ years: No effect No evidence of () publication bias. May use the CRF 1-hour maximum. CRF not intended from COMEAP () Lag 01. for health risk in a sensitivity Meta-analysis of 2 assessment. analysis. cities - Brisbane, Sydney. Low to moderate heterogeneity. lCD9: 410-413; ICDI0: I20-I22, I24, I25.2 Cardiac failure 15-64 years: No No effect n/a n/a n/a No CRF effect () recommended. 65+ years: No effect Random effects () estimate. No effect in 1-hour maximum. 24-hour average. Australian 2-cities Lag 01. No evidence of meta-analysis ().
Meta-analysis of 2 cities - Brisbane, Sydney. High heterogeneity. for 65+ years lCD9: 390-429; ICDI0: I00-I52, I97.0, I97.1, I98.1 assessment. analysis. Ischaemic heart disease Not assessed in 4 cities study () 15-64 years: No effect 65+ years: No effect () 1-hour maximum. Lag 01. Meta-analysis of 2 cities - Brisbane, Sydney. Low to moderate heterogeneity. lCD9: 410-413; ICDI0: I20-I22, I24, I25.2 1.2% (0.5-1.9%) per 10 ug/m3 () Random effects estimate. 24-hour average. No evidence of publication bias. CRF not intended for health risk assessment. n/a n/a n/a No CRF recommended. No effect in Australian 2-cities meta-analysis (). May use the CRF from COMEAP () in a sensitivity analysis. Cardiac failure 15-64 years: No effect 65+ years: No effect () 1-hour maximum. Lag 01. No effect () Random effects estimate. 24-hour average. No evidence of n/a n/a n/a No CRF recommended. No effect in Australian 2-cities meta-analysis ().